November 16th, 2011
ELEVATE-TIMI 56: One New Piece of the Clopidogrel Puzzle
Larry Husten, PHD
Tripling the maintenance dose of clopidogrel in most but not all patients with a common genetic variation will lower platelet reactivity to levels achieved in patients without the variation.
September 21st, 2011
More Data but No Answers About Platelet Function Testing
Larry Husten, PHD
The RECLOSE 2–ACS (Responsiveness to Clopidogrel and Stent Thrombosis 2–ACS) trial from Italy provides new information about platelet reactivity but doesn’t answer any of the key questions about the possible role of platelet function testing in clinical practice. In a paper published in JAMA, Guido Parodi and colleagues report on 1,789 ACS patients who underwent PCI and who […]
March 28th, 2011
Updated Unstable Angina/Non-STEMI Guidelines Released by ACC & AHA
Larry Husten, PHD
The AHA and ACC have released a focused update of the 2007 guidelines for the management of unstable angina and non-STEMI. The guidelines incorporate new information from recent clinical trials, and deal with controversial topics such as the choice of antiplatelet agents, the use of platelet-function and genetic tests with antiplatelet agents, and the timing […]
NEJM Journal Watch — Recent Cardiology Articles- Transcatheter Valve Replacement for Severe Tricuspid Regurgitation
- Time in Blood Pressure Target Range and Outcomes in Hypertension: Real-World Data
- When to Start Anticoagulation After Ischemic Stroke in Patients with Atrial Fibrillation
- Aortic-Valve Replacement vs. Clinical Surveillance for Asymptomatic Severe Aortic Stenosis
- Secondary Hypertension in Young Adults